The University of Texas MD Anderson Cancer Center
Department of Lymphoma/Myeloma

Our group is the first to develop chimeric antigen receptor (CAR) T cell therapy specifically designed to target and control life-threatening fungal infections, including aspergillosis, candidiasis, and cryptococcosis. These infections pose a severe threat to immunocompromised individuals, such as cancer patients, organ transplant recipients, and people living with HIV/AIDS. Current treatment options for drug-resistant fungal infections are limited and often ineffective. Our novel technology harnesses the specificity and cytotoxic potential of the adaptive immune system by engineering CAR T cells to recognize and eliminate fungal pathogens.

We have successfully developed CAR T cells that target Aspergillus, Candida, and Cryptococcus species, and are currently conducting ongoing preclinical characterization studies to further validate their efficacy and safety.

MDACC Faculty

OCRID

LOOP

Google Scholar

Education & Training

PhD, University of Madras, 1995

Faculty Development

• Mentoring Works

---